|
|
Жизнь |
|
|
|
| ||||
Списоклитературы1. Eric Wespes, Edouard Amar, Dimitrios Hatzichristou, Kosta Hatzimouratidis, Francesco Montorsi, John Pryor, Yoram Vardi // EAU Guidelines on Erectile Dysfunction: An Update, european urology 49. -2006.- P. 806-815. 2. Mazo EB, Gamidov SI, Iremashvili VV. Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernous arteries? A pilot study // BJU Int. - 2006. - 98. - P. 1054-1058. 3. Chia SJ, Ramesh К et al. Clinical application of prognostic factors for patients with organic causes of erectile dysfunction on lOOmg of sildenafil citrate // Int J Urol. -2004. - 11 (12). -P. 1104-1109. 4. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes // Diabetes Care. - 2002. -25.-P. 2159-64. 5. Bella AJ, Deyoung LX, Al-Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications // Eur Urol. - 2007. - 52. - P. 990-1005. 6. Montorsi F, Briganti A, Salonia A, et-al. Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction? // Eur Urol. - 2006. - 49. - P. 979-986. 7. McMahon CG. Treatment of erectile dysfunction with chronic dosing of tadalafil // Eur Urol. - 2006. - 50. - P. 215-217. 8. Park JW, Mrowietz C, Chung N, Jung F. Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study // Clin Hemorheol Microcirc - 2004 - Vol. 31 - P. 173-183. 9. Dishy V, Harris PA, Pierce R, Prasad HC, Sofowora G, Bonar HL, Wood AJ, Stein CM. Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers // Br J Clin Pharmacol. - 2004. - 57(2). - P. 209-12. 10. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction // J Urol. - 1999. - Vol. 161. - P. 5-11. 11. Гамидов СИ, Иремашвили ВВ. Виагра - прошлое, настоящее и будущее // Русский Медицинский Журнал. - 2005. - 13 (25). - С. 1683-1687. 12. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study // J Urol. - 1994. - Vol. 151(1). - P. 54-61. 13. Braun M, Wassner G, Klotz T et al. Epidemiology of erectile dysfunction: results of the "Cologne Male Survey" // Int J Impot Res. - 2000. - Vol. 12. -P. 305-311. 14. Chew KK, Earle CM, Stuckey BGA et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates // Int J Impot Res. — 2000.-Vol. 12.-P. 41-45. 15. Parazzini F, Menchini FF, Bortolotti A et al. Frequency and determinants of erectile dysfunction in Italy // Eur Urol. - 2000. - Vol. 37. - P. 43-49. 16. Ponholzer A, Temml C, Mock К et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire // Eur Urol. - 2005. - Vol. 47. - P. 80-85. 17. Мазо Е.Б., Гамидов СИ., Иремашвили В.В. К вопросу о патогенезе артериогенной эректильной дисфункии // Врачебное сословие. - 2006. -1-2.-С. 4-7. 18. Лоран О.Б., Щеплев П.А., Нестеров С.Н., Кухаркин С.А. Современные методы диагностики и лечения эректильных дисфункций // Русский Медицинский Журнал. - 2000. - 3. - С. 130-134. 19. Гамидов СИ., Иремашвили В.В. Эректильная дисфункция и сердечно-сосудистые заболевания: новый взгляд на старую проблему // Кардиоваскулярная терапия и профилактика. - 2006. - 6. - С. 123-128. 20. Braun M, Evers T, Merchant S, Hellmich M. Development of a simple tool estimating the risk of erectile dysfunction // J Sex Med. - 2004. - Vol. l(suppl 1). -34. - Abstract 017. 21. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine // J Sex Med. - 2006. - Vol. 3. - P. 28-36. 22. Berner M, Althof SE, Goldstein I, Cappelleri JC et al. Relationship between erection hardness and confidence in men with erectile dysfunction treated with sildenafil citrate // J Sex Med. - 2008. - Vol. l(suppl 149). -1. - Abstract MP-026. 23. Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial dysfunction? Results from a retrospective cohort study // Int J Impot Res. -2004. - Vol. 16. - P. 350-353. 24. Ponhoizer A, Temml C, Obermayr R et al. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? // Eur Urol.-2005.-Vol. 48.-P. 512-518. 25. Seftel A. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction // J Urol. - 2006. - Vol. 175. - P. 1824. 26. Shamloul R, Ghanem HM, A Salem et al. Correlation between penile duplex findings and stress electrocardiography in men with erectile dysfunction // Int J Impot Res. - 2004. - Vol. 16. - P. 235-237. 27. Марков X. М. Молекулярные механизмы дисфункции сосудистого эндотелия // Кардиология. — 2005. - 12. — С. 62-67. 28. Малая Л.Т., Корж А.Н., Балковая Л.Б. Эндотелиальная дисфункция при патологии сердечно-сосудистой системы // Харьков: ТОРСИНГ. -2000.-С. 432. 29. Gimbrone MA, Topper JN, Nagel T et al. Endothelial Dysfunction, Hemodynamic Forces, and Atherogenesis // Ann. N.Y. Acad. Sci. - 2000. -Vol. 902.-P. 230-240. 30. Vanhoutte PM. Endothelial Control of Vasomotor Function // Circ J. -2003.-Vol. 67. -P. 572-575. 31. Щеплев П.А, Тополянский А.В., Жиленко В.В., Носовицкий П.Б. Эректильная дисфункция и сердечно-сосудистые заболевания // Медицинская кафедра. - 2002. - 2. - С. 68-73. 32. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease // Int J Clin Pract. - 2005. - Vol. 59. - P. 225-229. 33. Montorsi P, Roumeguere T, Montorsi F et al. Is there a link between erectile dysfunction and coronary artery disease? // EAU Update series. -2004.-Vol. 2.-P. 43-48. 34. Costa CC, Soares RS, Castela AC, Adaes SA et al. Increased endothelial apoptotic cell density in human diabetic erectile tissue - comparison with clinical data // J Sex Med. - 2008. - Vol. l(suppl 149). -1. - Abstract PD-043. 35. EspositoK, GiuglianoF, Di Palo С et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial // JAMA. - 2004. - Vol. 291 (24). - P. 2978-2984. 36. Pourmand G, Alidaee MR, Rasuli S et al. Do cigarette smokers with erectile dysfunction benefit from stopping? a prospective study // BJU Int. - 2004.-Vol. 94. -P. 1310-1313. 37. Камалов А. А., Дорофеев С. Д., Ефремов Е. А. Кардиоваскулярные аспекты эректильной дисфункции // Consilium medicum. - 2004. -5.- С. 7-10. 38. Ковалев В.А., Королёва СВ., Камалов А.А. Фармакотерапия эректильной дисфункции // Урология. — 2000. — 1. — С. 33-38. 39. Ковалев В.А. Диагностика и лечение эректильной дисфункции: Дис. ... д-ра мед. наук. - Москва. - 2001. 40. Мазо Е.Б., Жуков О.Б., Зубарев А.Р. Виагра-тест в ультразвуковой диагностике эректильной дисфункции // Русский Медицинский Журнал. - 2003. - Т. 11. - С. 1333-1335. 41. Аляев Ю.Г., Винаров А.З., Ахвледиани Н.Д. Эректильная дисфункция новые аспекты патогенеза, профилактики и лечения эректильной дисфункции после трансуретральных операций по поводу гиперплазии предстательной железы // Consilium medicum. - 2007. -7.- С. 8-12. 42. Rodriguez JJ, Al Dashti R, Schwarz ER. Linking erectile dysfunction and coronary artery disease // Int J Impot Res. - 2005. - Vol. 17. - P. S12-S18. 43. Frei B. On the role of vitamin С and other antioxidants in atherogenesis and vascular dysfunction // Proc Soc Exp Biol Med. - 1999. - Vol. 222. -P. 196-204. 44. Hedlund P, Aszodi A, Pfeifer A et. al. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice // Proc Natl Acad Sci USA. - 2000. — Vol. 97.-P. 2349-2354. 45. Kanani PM, Sinkey CA, Browning RL et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans //Circulatin. - 1999. -Vol. 100.-P. 1161-1168. 46. Katz SD, Balidemaj K, Homma S, et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure // J Am Coll Cardiol. - 2000. - Vol. 36. - P. 845-851. 47. Rosano GM, Aversa A, Vitale С et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk // Eur Urol. - 2005. - Vol. 47. - P. 214-220. 48. Gonzales-Cadavid NF, Burnett AL, Magee TR, Zeller CB. Expression of penile neuronal nitric oxide synthase variants in the rat and mouse penile nerves. Biol Reprod. 2000. - Vol. 63. - P. 704-714. 49. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vase Biol 2007. - Vol. 27. -P. 15-26. 50. Azadzoi KM, Schulman RN, Aviram M, Siroky MB. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants // J Urol.-2005.-Vol. 174.-P. 386-393. 51. Ryu JK, Kim DY, Lee T et al. The role of free radical in the pathogenesis of impotence in streptozotocin-induced diabetic rats // Yonsei Med J. -2003. - Vol. 44. - P. 236-241. 52. Rajfer J. Endothelial dysfunction as a cause of erectile dysfunction— misdiagnosis or misnomer? // Urology. - 2004. - Vol. 64. - P. 193-194. 53. Мазо Е.Б., Гамидов СИ., Иремашвили В.В. К вопросу о патогенезе артериогенной эректильной дисфункии // Врачебное сословие. -2006.-1-2.-С. 4-7. 54. Rybalkin SD, Yan С, Bornfeldt KE et al. Cyclic GMP phosphodiesterases and regulation of smooth muscle function // Circ Res. - 2003. - Vol. 93. -P. 280-291. 55. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress // Circ Res. - 2000. - Vol. 87. - P. 840-844. 56. Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: history and impact on cardiovascular disease // Vase Pharmacol. - 2006. - Vol. 45.-P. 268-276. 57. Мазо Е.Б., Гамидов СИ., Овчинников Р.И., Иремашвили В.В. Этиология, патогенез, диагностика и лечение эректильной дисфункции у пожилых // Фарматека. - 2005. - 4/5(100). - С. 40-45. 58. Иремашвили В.В. Значение исследования эндотелиальной функции у больных эректильной дисфункцией: Дис. ... к-та мед. наук. - Москва, -2006. 59. Cook JP. Does ADMA cause endothelial dysfunction? // Arterioscler Thromb Vase Biol. - 2000. - Vol. 20. - P. 2032-2037. 60. Мазо Е.Б., Гамидов СИ., Иремашвили В.В. Роль эндотелиальной дисфункции кавернозных артерий в патогенезе эректильной дисфункции у больных метаболическим синдромом // Тезисы научно-практической конференции, посвященной 300-летию основания Главного военного клинического госпиталя имени академика Н.Н.Бурденко. М., - 2006. - С 119. 61. Boger RH, Bode-Boger SM, Szuba A et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia // Circulation. - 1998. - Vol. 98. - P. 1842-1847. 62. Surdacki S, Nowicki M, Sanmann J et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with . essential hypertension // J Cardiovasc Pharmacol. - 1999. - Vol. 33. - P. 652-658. 63. Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications // Am J Cardiol. - 2002. - Vol. 90. - P. 40L-48L. 64. Mazo E, Gamidov S, Ovchinnikov R, Andranovich S, Iremashvili V. Assessment of cavernosal arteries endothelial function in diagnosis of arteriogenic erectile dysfunction // 8th Congress of the European Society for Sexual Medicine. Copenhagen, Denmark, December 4-7, 2005. Book of abstracts. J Sex Med 2005. - P. 07-312. 65. Королева О.С., Затейщиков Д.А. Биомаркеры в кардиологии: регистрация внурисосудистого воспаления // Фарматека - 2007. -8/9.-С. 143. 66. Соболева Е.В. Гомоцистеинемия как мишень терапевтического воздействия у больных ишемической болезнью сердца. Эффекты симвастина // Болезни сердца и сосудов -2007. - 2. 67. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease // Lancet. -1999.-Vol. 354.-P. 407-^13. 68. Genser D. Homocysteine, vitamins, and restenosis after percutaneous coronary intervention // Cardiovasc Rev Rep. - 2003. - Vol. 24 (5). - P. 253-8. 69. Kanani P, Sinkey C, Browning R et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans // Circulation. - 1999. -Vol. 100. -P. 1161-8. 70. Гамидов СИ. Эректильная дисфункция у больных с метаболическим синдромом: эпидемиология, патогенез, диагностика, лечение и профилактика: Диссер. ... д-ра мед. наук. - Москва. - 2007. 71. Мазо Е.Б., Гамидов СИ., Иремашвили В.В., Сотникова Е.М. Роль препаратов тестостерона в комбинированной терапии эректильной дисфункции у больных с метаболическим синдромом // Урология. -2007.- 4.-С. 63-66. 72. Fu W, Dudman N, Perry M, Wang X. Homocysteinemia attenuates hemodynamic responses to nitric oxide in vivo // Atherosclerosis - 2002; — Vol. 161(1).-P. 169-76. 73. Lang D, Kredan MB, Lang D, Moat SJ et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: Role for superoxide anions // Arterioscler Thromb Vase Biol — 2000. 74. Bots M, Launer L, Lindemans J et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly // The Rotterdam Study. Arch Intern Med. - 1999. - Vol. 159. - P. 38. 75. Hatzichristou D, Hatzimouratidis K, Bekas M et al. Diagnostic steps in the evaluation of patients with erectile dysfunction // J Urol. - 2002. — Vol. 168.-P. 615-620. 76. Montorsi F. Assessment, diagnosis, and investigation of erectile dysfunction // Clin Cornerstone. - 2005. - Vol. 7. - P. 29-35. 77. Lue TF, Hricak H, Marich KW et al. Vasculogenic impotence evaluated by high-resolution ultrasonography and pulsed Doppler spectrum analysis // Radiology. - 1985. - Vol. 155. - P. 777-78L 78. Верткий А.Л., Зорина С.А., Новикова И.М., Зимин О.Н. Эффективность и безопасность метаболической фармакотерапии эректильной дисфункции у больных диабетической нейропатией // Consilium medicum. - 2008. - 4.- С. 7-10. 79. Мазо Е.Б., Гамидов СИ., Овчинников Р.И., Андранович СВ., Иремашвили В.В. Посткомпрессионный тест в диагностике васкулогенной эректильной дисфункции // Урология. -2005. 4. - С. 64-69. 80. Altinkilic В, Hauck EW, Weidner W. Evaluation of penile perfusion by color-coded duplex sonography in the management of erectile dysfunction // World J Urol. - 2004. - Vol. 22. - P. 361-364. 81. Aversa A, Bruzziches R, Spera G. Diagnosing Erectile Dysfunction: The penile dynamic colour duplex ultrasound revisited // Int J Androl. - 2005. -Vol. 28.-P. 61-63. 82. Eardley I. Imaging for erectile dysfunction // Curr Opin Urol. - 2002. - Vol. 12.-P. 143-147. 83. Пушкарь Д.Ю. Эректильная дисфункция - современные методы диагностики и лечения // Справочник поликлинического врача. -2004.- 2.- С. 29-31. 84. Asian D, Esen A, Secil M. A new method for the evaluation of erectile dysfunction: sildenafil plus doppler ultrasonography // J Urol. - 2001. -Vol. 166.-P. 181-184. 85. Bacar MM, Batislam E, Altinok D et al. Sildenafil citrate for penile hemodynamic determination: an alternative to intracavernosal agents in Doppler ultrasound evaluation of erectile dysfunction // Urology. - 2001. — Vol. 57.-P. 623-626. 86. Speel TG, Bleumer I, Diemont WL et al. The value of sildenafil as mode of stimulation in pharmaco-penile duplex ultrasonography // Int J Impot Res. -2001.-Vol. 13.-P. 189-191. 87. Ovchinnikov R, Mazo E, Gamidov S, Andranovich S, Iremashvili V. New approach in diagnostic of erectile dysfunction by penile doppler ultrasound with vardenafil hydrochloride (Levitra-test) versus alprostadil intracavernous injection // J Sex Med 2005. - Vol. 2 (suppl. 1). - P. 042. 88. Cornud F, Amar E, Hamida К et al. Imaging in male hypofertility and impotence // BJU Int. - 2000. - Vol. 86 (suppl 1). - P. 153-163. 89. Wespes E, Amar E, Hatzichristou D et al. EAU Guidelines on Erectile Dysfunction: An Update // Eur Urol. - 2006. - Vol. 49 - P. 806-815. 90. Aversa A, Isidori AM, Caprio M et al. Penile pharmacotesting in diagnosing male erectile dysfunction: evidence for lack of accuracy and specificity // Int J Androl. - 2002. - Vol. 25. - P. 6-10. 91. Мазо Е.Б., Гамидов СИ., Жученко Т.Д., Андранович СВ., Овчинников Р.И., Иремашвили В.В. Левитра-тест в диагностике васкулогенной эректильной дисфункции // Урология. - 2005. 1. - С. 29-31. 92. Michal V, Pospichal J. Phalloarteriography in the diagnosis of erectile impotence // World J Surg. - 1978. - Vol. 2. - P. 239-248. 93. Еркович А.А. Патогенетические закономерности формирования васкулогенной эректильной дисфункции: Диссер. ... д-ра мед. наук. — Новосибирск. - 2007. 94. Gerstenberg ТС, Levin RJ, Wagner G. Journal Article // Urol Nurs. - 2006. - Vol. 20. - P. 326-330. 95. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis // Lancet. - 1992. - Vol. 340. - P. 1111-1115. 96. Kaiser DR, Billups K, Mason С et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease // J Am Coll Cardiol. -2004. -Vol. 43. -P. 179-184. 97. Иванова О.В., Рогоза А.Н., Балахонова Т.В. и др*. Определение чувствительности плечевой артерии к напряжению сдвига на эндотелии как метод оценки состояния эндотелий зависимой вазодилатации с помощью ультразвука высокого разрешения у больных артериальной гипертонией // Кардиология. - 1998. - 3. -С. 37-42. 98. Liao Ж. Endothelium and acute coronary syndromes // Clin Chem. — 1998. - Vol. 44. -P. 1799-1808. 99. Kuvin JT, Karas RH. Clinical utility of endothelial function testing. Ready for prime time? // Circulation. - 2003. - Vol. 107. - P. 3243-3247. 100. Virag R. Flow-dependent dilatation of the cavernous artery. A potential test of penile NO content // J Mai Vase. - 2002. - Vol. 27. - P. 214-217. 101.Mazo E, Gamidov S, Andranovich S, Iremashvili V. Testing endothelial function of brachial and cavernous arteries in patients with erectile dysfunction // J Sex Med 2006. - Vol. 3. - P. 323-330. 102. Dimmeler S, Fleming I, Fisslthaler В et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation // Nature. -1999.-Vol. 399. -P. 601-605. 103. Mazo E, Gamidov S, Mamedov M, Iremashvili V. Prophylaxis of erectile dysfunction in men with metabolic syndrome: a pilot study // European urology supplement, 2008; 7 (3). P 897. 104. Leeson P, Thorne S, Donald A et al. Non-invasive measurement of endothelial function: effect on brachial artery dilation of graded endothelial dependent and independent stimuli // Heart. - 1997. - Vol. 78. -P. 22-27. 105.Gaeta G, De Michele M, Guomo S et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction // N Engl J Med. - 2000. - Vol. 343. - P. 840-846. 106. Mazo E, Gamidov S, Iremashvili V. The effect of vardenafil (Levitra) on endothelial function of cavernous and brachial arteries in patients with erectile dysfunction // Eur Urol suppl. - 2006; - Vol. 5. - P. 317. 107. Мазо Е.Б., Гамидов СИ. Оценка эндотелиальной функции у больных артериогенной эректильной дисфункцией // Методические рекомендации. - М.: ГОУ ВПО РГМУ Росздрава. - 2007. - С. 17. 108. Angerer Р, Negut С, Sturk S. Endothelial function of the popliteal artery in patients with coronary artery disease // Atherosclerosis. - 2001. - Vol. 155.-P. 187-193. 109. Rubenfire M, Cao N, Smith DE et al. Carotid artery reactivity to isometric hand grip exercise identifies persons at risk and with coronaiy disease // Atherosclerosis. - 2002. - Vol. 160. - P. 241-248. 110. Неймарк А. И., Баканова А. С. Гемодинамика полового члена в норме и при васкулогенной эректильной дисфункции // Урология. - 2008. — 2. - С. 40-44. 111. Faria-Neto JR, Chagas AC, Bydlowski SP, et al. Hyperhomocystinemia in patients with coronary artery disease // Braz J Med Biol Res. - 2006. -Vol. 39 (4).-P. 455-63. 112. Kazemi MB, Eshraghian K, Omrani GR, et al. Homocysteine level and coronary artery disease // Angiology. - 2006. - Vol. 57(1). - P. 9-14. 113.Mazo E, Gamidov S, Mamedov M, Iremashvili V. Association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and erectile dysfunction in patients with metabolic syndrome // Int J of Impot Research. - 2008. - 20. - P. 68-72. 114. Schwartz RG, Pearson ТА, Kalaria VG. Prospective serial evaluation of myocardial perfusion and lipids during the first 6 months of pravastatin therapy: coronary artery disease regression SPECT monitoring trial // J Am Coll Cardiol. - 2003. - Vol. 42. - P. 600-610. 115. Lavrencic A, Salobir BG, Keber I. Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome // Arterioscler Thromb Vase Biol. - 2000. - Vol. 20. - P. 551-555. 116. Maiorana A, O'Driscoll G, Cheetham С et al. The effect of combined aerobic and resistence exercise training on vascular function in type 2 diabetes // J Am Coll Cardiol. - 2001. - Vol. 38. - P. 860-866. 117. Sasaki S, Higashi Y, Nakagawa К et al. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension // Am J Hypertens. - 2002. - Vol. 15. - P. 302-309. 118. Hamdy O, Ledbury S, Mullooly С et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome //Diabetes Care. -2003. -Vol. 26 -P. 2119-2125. 119. PourmandG, AlidaeeMR, Rasuli S et al. Do cigarette smokers with erectile dysfunction benefit from stopping? a prospective study // BJU Int. -2004.-Vol. 94.-P. 1310-1313. 120. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Эндотелиальная функция при сердечной недостаточности: возможности терапии ингибиторами ангиотензин-превращающего фермента // Кардиология. - 2001. - 5. -С. 30-45. 121. Амарантова Л.Г., Берг М.Д., Ховаева Я.Б., Головской Б.В.. Влияние лизиноприла на функцию эндотелия и гладких мышц периферических сосудов у больных артериальной гипертензией // Лечебное дело. - 2005. - 3. - С. 42-46. 122. Mullen MJ, Clarkson P, Donald AE et al. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study // J Am Coll Cardiol. - 1998. - Vol. 31. - P. 1330-1335. 123. Muiesan ML, Salvetti M, Monteduro С et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension // Hypertension. - 1999. - Vol. 33. - P. 575-580. 124. Taddei S, Virdis A, Ghiadoni L et al. Different effects of a calcium-antagonist and a beta-blocker on nitric oxide availability in essential hypertensive patients // J Hypertens. - 1999. - Vol. 17. - P. 129. 125. Carr AC, Zhu BZ, Frei B. Potential Antiatherogenic Mechanisms of Ascorbate (Vitamin C) and «-Tocopherol (Vitamin E) // Circ Res. - 2000. -Vol. 87.-P. 349-354. 126. Doshi SN, McDowell IF, Moat SJ et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? // Arterioscler Thromb Vase Biol. - 2001. - Vol. 21.-P. 1196-1202. 127. Korantzopoulos P, Galaris D. The protective role of vitamin С on endothelial dysfunction // J Clin Basic Cardiol. - 2003. - Vol. 6. - P. 3-5. 128. Verhaar MC, Stroes E, Rabelink TJ. Folates and Cardiovascular Disease // Arterioscler Thromb Vase Biol. - 2002. - Vol. 22. - P. 6-13. 129. D'Uscio LU, Milstien S, Richardson D et al. Long-term vitamin С treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity // Circ Res. - 2003. - Vol. 92. - P. 88-95. 130. Martinez-Jabaloyas JM, Gil-Salom M, Villamon-Fort R. Prognostic factors for response to sildenafil in patients with erectile dysfunction // Eur Urol. -2001.-Vol. 40.-P. 641-646. 131. Stroes ESG, van Faassen ЕЕ, Yo M et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase // Circ Res. - 2000. - Vol. 86. - P. 1129 -1134. 132. Ulker S, McKeown PP, Bayraktutan U. Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities // Hypertension. - 2003. - Vol. 41. - P. 534-539. 133. Bellamy MF, McDowell IFW, Ramsey MW et al. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects // Eur J Clin Invest. - 1999. - Vol. 29. - P. 659-662. 134. Woo KS, Chook P, Lolin YI, Sanderson JE et al. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia // J Am Coll Cardiol. - 1999. -Vol. 34. -P. 2002-2006. 135. Chen J, Wollman Y, Chernichovski T et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study // BJU Int. - 1999. - Vol. 83. - P. 269-273. 136. Guigliano D, Marfella R, Verrazzo G et al. The vascular effects of L-arginine in humans. The role of endogenous insulin // J Clin Invest. — 1997.-Vol. 99.-P. 433-438. 137. Chen J, Wollman Y, Chernichovski T et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study // BJU Int. - 1999. - Vol. 83. - P. 269-273. 138. Verrazzo G, Marfella R et al. The vascular effects of L-arginine in humans // J Clin Invest. - 2000. - Vol. 90. - P. 433-436. 139. Eardley L, Sethia K., Dean J. Erectile dysfunction: assessment and management in primary care // London. - Mosby-Wolfe Publications. -1998.-Vol. 59. 140. Reffelmann T, Kloner RA. Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease // Circulation. - 2003. - Vol. 15. - P. 239-44. 141. Lue TF. Erectile dysfunction // N. Engl. J. Med. - 2000. - Vol. 342(24). -P. 1802-1813. 142. Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract // Urology. - 2002. - Vol. 60. - P. 13-20. 143.Nicolosi A, Laumann EO, Glasser DB, et al. Global Study of Sexual Attitudes and Behaviors Investigators' Group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors // Urology. - 2004. - Vol. 64. - P. 991-97. 144. Fink HA, Mac Donald R, Rutks IR, et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis // Arch Intern Med. -2002.-Vol. 162.-P. 1349-60. 145. Montorsi F, Creanga DL and Stecher VJ. Safety and tolerability of sildenafil in older men // J Sex Med. - 2008. - Vol. l(suppl 149). -1. Abstract PD-05 7. 146. Sommer F, Klotr T, Mathers MI, et al. A comparative randomised multicentre study of the maximum dose of sildenafil, tadalafil and vardenafil // Eur Urol Suppl. - 2004. - Vol. 3. - P. 105. Abstracts 409-10. 147. Sommer F, Mathers M, Klotz T, et ai. Which PDE5-inhibitor do patients prefer? A comparative study of 50 mg sildenafil, 10 mg tadalafil and 10 mg vardenafil // Eur Urol Suppl. - 2004. - Vol. 3. - P. 105. 148.Markou S, Perimenis P, Gyftopoulos K, et al. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports // Int J Impot Res. - 2004. - P. 100. 149. Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update // BJU Int. - 2004. - Vol. 93. - P. 1276-81. 150. Abdo CH, Afif-Abdo J et al. Counseling, phosphodiesterase-5 inhibitor or both: three therapeutics approaches in 120 patients with erectile dysfunction // J Sex Med. - 2008. - Vol. 1. - 1. - P. PD-058. 151. Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil // Int J Irapot Res. - 2001. - Vol. 13. - P. 282-90. 152. Thadani U, Smith W. The Effect of Vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease // 1 Am Coll Cardio. - 2002. - Vol. 40:11. 153. Мазо Е.Б., Гамидов СИ., Овчинников Р.И., Муфагед М.Л., Сотникова Е.М. Сиалис в лечении больных с эректильной дисфункцией: наш клинический опыт // Вестник РГМУ. - 2008. - 5. - С. 20-23. 154. Porst H., Arnds S., Kleingarn M. A comparator trial between Sildenafil, Tadalafil and Vardenafil - Preliminary results in 150 patients // Int J Impot Res.- 2003.-Vol. 15.-P. S5. 155.Govier F, Potempa AJ, Kaufman J, et al. A multi-center, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction // Clin Ther. - 2003. - Vol. 25. - P. 2709-23. 156. Rodriguez J, Cuadrado JM, Munoz J, and Franco E. Effectiveness and preference study in patients with severe erectile dysfunction, after taking the three phosphodiesterase-5 inhibitors // J Sex Med. - 2008. - Vol. 1. -1. -P.MP-028. 157. Claes HIM, Van Poppel H. The use of sildenafil, tadalafil, and vardenafil in clinical practice // J Sex Med. - 2004. - Vol. 1. - P. 043. 158. Eardley I., Mirone V., Montorsi F., Ralf D. et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy // BJU Urol . - 2005. - Vol. 95 - P. 1323-1332. 159. Min KS, Kang DI, Kwak HS et al. Effect of diet-control and phosphodiesterase type 5 inhibitor on endothelial function in high cholesterol-diet rats // J Sex Med. - 2008. - Vol. 1. -1. - P. PD-029. 160. Hwang I-C, Lee DW, Kim SJ et al. Erectogenic effect and pharmacokinetic study of potent and selective phosphodiesterase type 5 inhibitor, CKD-533 // J Sex Med. - 2008. - Vol. 1. - 1. - P. PD-051. 161. Desouza C, Parulkar A, Lumpkin D et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes // Diabetes Care. - 2002 - Vol. 25 - P. 1336-1339. 162. Kimura M, Higashi Y, НагаК et al. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers // Hypertension -2003-Vol. 41-P. 1106-1110, 163. Park JW, Mrowietz C, Chung N, Jung F. Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study // Clin Hemorheol Microcirc - 2004 - Vol. 31 - P. 173-183. 164. Berner M, Althof SE, Goldstein I, Cappelleri JC et al. Relationship between erection hardness and confidence in men with erectile dysfunction treated with sildenafil citrate // J Sex Med. - 2008. - Vol. 1. -1. - P. MP-026. 165. Gori T, Sicuro S, Dragoni S et al. Sildenafil Prevents Endothelial Dysfunction Induced by Ischemia and Reperfusion via Opening of Adenosine Triphosphate-Sensitive Potassium Channels // A Human In Vivo Study Circulation. - 2005. - Vol. 111. - P. 742-6. 166. Gross GJ. Sildenafil and Endothelial Dysfunction in Humans // Circulation.-2005.-Vol. 111.-P. 721-723. 167. Vlachopoulos C, Rokkas K, IoakeimidisN et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study // Eur Urol. -2005. - Vol. 48-P. 996-1002 168. Halcox JP, Nour KR, Zalos G et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia // J Am Coll Cardiol. - 2002. - Vol. 40 - P. 1232-1240. 169. Аляев Ю.Г., Ронкин М.А., Есилевский Ю.М. и др. Системный подход к изучению действия препарата Левитры у больных хроническим простатитом и эректильной дисфункцией // Урология. - 2005. - 2. -С.53-59. 170. Ahlen van H, Zumbe J, and Hanisch Ulrich J. The real-life safety and efficacy of vardenafil (realise) study: results in men with erectile dysfunction and underlying conditions from Europe and overseas // J Sex Med. -2008. -Vol. 1. -1. -P. MP-023. 171. Мазо Е.Б., Гамидов СИ., Иремашвили В.В. Действие варденафила на эндотелиальную функцию и его эффективность в лечении эректильной функции // Вестник РГМУ. - 2006. - 5(52). - С. 34-40. 172. Аляев Ю.Г., Винаров А.З., Чалый М.Е., Демидов Ю.Л., Ахвледиани Н.Д. Причины эректильной дисфункции после трансуретральной резекции гиперплазированной предстательной железы и ее профилактика // Урология. - 2005. - 3. - С. 28-32. 173. Ефремов Е. А., Дорофеев С. Д. Медикаментозная терапия эректильной дисфункции // РМЖ. - 2003. - 24. СИ. 174. Мазо Е.Б., Гамидов СИ., Иремашвили В.В. Эректильная дисфункция // Монография. Москва. - 2008. 175.Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta // J Pharmacol Exp Ther. - 2006. - Vol. 316(2). - P. 654-61. 176. Dishy V, Sofowora G, Harris PA et al. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men // Clin Pharmacol Ther - 2001 -Vol. 70-P. 270-279 177. Dishy V, Harris PA, Pierce R et al. Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers // Br J Clin Pharmacol. - 2004. - Vol. 57 - P. 209-212 178. Robinson SD, Ludlam CA, Boon NA, Newby DE. Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease // Heart. - 2006. - Vol. 92(2). - P. 170-6. 179. Камалов А. А., Дорофеев С. Д., Ефремов Е. А. Кардиоваскулярные аспекты эректильной дисфункции // Consilium medicum. - 2004. -5.-С. 7-10. 180. Martin-Morales A, Cambau О, Debruyne F, Buvat J et al. Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomised, double-blind,placebo-controlled study // J Sex Med. - 2008. - Vol. 1. -1. - P. PD-053. 181. Montorsi F, Briganti A, Salonia A, et al. Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction? // Eur Urol. - 2006. - Vol. 49. - P. 979-986. 182. Verheyden B, Roumeguere T, Bitton A et al. Effect of 12 months tadalafil treatment for erectile dysfunction on couple relationships: results from the detect study // J Sex Med. - 2008. - Vol. 1. -1. - P. PD-054. 183. Hellstrom WJ. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors // Int J Clin Pract. - 2007. - Vol. 61(9).-P. 1547-1554. 184. McMahon CG. Comparison, efficacy, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction //J Sex Med.-2005.-Vol. 2.-P. 415^25. 185.Porst H, Rubio-Aurioles E, Kim ED, Rosen RC et al. Impact on erectile function and sexual quality of life of couples: a randomised, double-blmd,placebo-controlled trial of tadalafil taken once daily // J Sex Med. -2008. - Vol. 1. -1. - P. PD-080. 186. AhnGJ, YuJY, Choi SM et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes // Int J Androl. - 2005. - Vol. 28. - P. 260-266. 187. Casperson JM, Steidle CP, Pollifrone DL. Penile rehabilitation in a community setting // J Sex Med. - 2007. - Vol. 4. - P. 85-86. 188. Sommer F, Schulze W. Treating erectile dysfunction by endotheliai rehabilitation with phosphodiesterase 5 inhibitors // World J Urol. - 2005. -Vol. 23.-P. 385-392. 189. Buvat J, Faria G, Wetterauer U, et al. Tadalafil 5mg and 10 mg taken once a day for the treatment of erectile dysfunction improves patient sexual satisfaction // J Sex Med. - 2007. - Vol. 4. - P. 91. 190. McMahon CG. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to ondemand tadalafil // J Sex Med. — 2004. - Vol. 1. - P. 292-300. 191.Hatzimouratidis K, Moysidis K, Bekos A, et al. Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study // Eur Urol. -2006.-Vol. 50.-P. 126-133. 192. Seftel AD, Buvat J, Althof SE, Burns P et al. Improvement in confidence, sexual, relationship, and satisfaction measures in a randomized treal of tadalafil 5 mg taken once daily // J Sex Med. - 2008. - Vol. l(suppl 149). -l.-P. PD-081. 193. Bella AJ, Deyoung LX, Al-Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications // Eur Urol. - 2007. - Vol. 52. - P. 990-1005. 194. Padma-Nathan E, McCuUough AR, Giuliano F et al. Postoperative nightly administration of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy // J Urol. - 2003. - Vol. 4(Suppl). - P. 375 195. McMahon CG. Treatment of erectile dysfunction with chronic dosing of tadalafil//Eur Urol.- 2006.-Vol. 50.-P. 215-217. 196. Aversa A, Greco E, Bruzziches R, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study // Int J Impot Res. - 2007. - Vol. 19.-P. 200-207. 197. Rosano GM, Aversa A, Vitale С et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk // Eur Urol. - 2005. - Vol. 47 - P. 214-220. 198. Аляев Ю. Г., Винаров А. 3., Ахвледиани Н. Д. Опыт длительного и непрерывного лечения варденафилом тяжелых форм нарушения эрекции // Урология. - 2005. - 5. - С. 64-66. 199. Аляев Ю. Г., Винаров А. 3., Ахвледиани Н. Д. Лечебный эффект курсового лечения ингибитором фосфодиэстеразы-5 варденафила при эректильной дисфункции // Урология. - 2007. - 1. - С. 45-49. 200. Martin-Morales, J. Maria Наго, A. Beardsworth, J. Bertsch. Therapeutic Effectiveness and Patient Satisfaction after 6 Months of Treatment with Tadalafil, Sildenafil, and Vardenafil: Results from the Erectile Dysfunction Observational study (EDOS) // Eur Urol. - 2007. - Vol. 51.-P. 541-550. 201. Caretta N, Palego P, Ferlin A, et al. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil // Eur Urol. - 2005. - Vol. 48. - P. 326-332. 202. Kangwon K, Sungsang K, Heecheoul S et al. The efficacy and safety of once-a-day dosing of udenafil in men with erectile dysfunction: a randomised, double-blind,placebo-controlled study // J Sex Med. - 2008. -Vol. l(suppl 149).-1. 203.Nicolosi A, Laumann EO, Glasser DB, et al. Global Study of Sexual Attitudes and Behaviors Investigators' Group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors // Urology. - 2004. - 64. - P. 991-97. 204. Wespes E, Amar E, Hatzichristou D et al. EAU Guidelines on Erectile Dysfunction: An Update // Eur Urol. - 2006. - Vol. 49. - P. 806-815. 205. Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists // Cur Urol Rep. - 2003. - Vol. 4. — P. 457-465. 206. Saenz de Tejada I, Angulo J, Cellek S et al. Physiology of erectile function //J Sex Med.-2004.-Vol. 1.-P. 254-265. 207. Велиев Е. И., Лоран О. Б. Лечение эректильной дисфункции после нервосохраняющей радикальной позадилонной простатэктомии // Урология.- 2006. -1.-С. 28-33. Гасанов Р.В. Влияние регуляторного приема ингибиторов фосфодиэстеразы 5 типа на эректильную и эндотелиальную функции у больных с артериогенной эректильной дисфункцией Назад | Оглавление | Вперед Похожие материалы
Дата публикации: 15 января 2017 . |
|
|
